Administration of biological therapy (BT) in rheumatoid arthritis (RA) patients is often associated with hematological complications, which result in switching among therapies. Thus, there is an instant need for suitable screening parameters that will help to individualize the therapy and minimize the onset of adverse effects. We analyzed the hematological profile of 99 RA patients receiving TNFα (Adalimumab - ADA, Golimumab - GOL, Etanercept - ETA) or IL-6 receptor (Tocilizumab - TCZ) inhibitors in order to find possible indicators to improve personalization of RA therapy. BTs significantly affect the levels of observed hematological parameters. In contrast to TNF-α inhibitors, TCZ normalized almost all monitored hematological parameters to values of healthy donors. Only GOL from the TNF-α inhibitors studied, was able to normalize neutrophil counts, as well as platelet indicators. Importantly, effects on the blood parameters (e.g. lymphocytes or platelet count) differ even within the same therapeutic group (anti-TNFα). Variable effects of individual biological agents in RA treatment point to importance to evaluate the patient's hematological profile to improve the selection of suitable BT. It will help to personalize the administration of BT and prevent unnecessary switching from an effective therapy just because of provocation of avoidable hematological complications.

Center of Experimental Medicine Slovak Academy of Sciences Institute of Experimental Pharmacology and Toxicology Bratislava Slovak Republic

Comenius University Faculty of Medicine 5th Department of Internal Medicine University Hospital Bratislava Bratislava Slovak Republic

Department of Cell Biology and Radiobiology Institute of Biophysics of the Czech Academy of Sciences v v i Brno Czech Republic

Department of Food Technology Faculty of Chemical and Food Technology Slovak University of Technology Bratislava Slovak Republic

See more in PubMed

Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstrom DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PloS One. 2012;7(1):e30275. doi: 10.1371/journal.pone.0030275. PubMed DOI PMC

Autrel-Moignet A, Lamy T. Autoimmune neutropenia. Presse Méd. 2014;43:e105–e118. doi: 10.1016/j.lpm.2014.02.007. PubMed DOI

Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H. Successful switch to golimumab for eosinophilia and skin symptoms related to multiple biologics in a patient with rheumatoid arthritis. Intern Med. 2017;56:1585–1590. doi: 10.2169/internalmedicine.56.8168. PubMed DOI PMC

Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996;7:157–161. PubMed

Bellucci E, Terenzi R, La Paglia GM, Gentileschi S, Tripoli A, Tani C, et al. One year in review 2016: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:793–801. PubMed

Bessissow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G. Non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012;36:312–323. doi: 10.1111/j.1365-2036.2012.05189.x. PubMed DOI

Boilard E, Blanco P, Nigrovic PA. Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol. 2012;8:534–542. doi: 10.1038/nrrheum.2012.118. PubMed DOI

Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-alpha (TNF-alpha) targeted biologics and recently licensed TNF-alpha inhibitors: data from clinical trials and national registries. J Rheumatol Suppl. 2014;91:56–64. doi: 10.3899/jrheum.140103. PubMed DOI

Cavill I, Auerbach M, Bailie GR, Barrett-Lee P, Beguin Y, Kaltwasser P, et al. Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin. 2006;22:731–737. doi: 10.1185/030079906X100096. PubMed DOI

Chara L, Sanchez-Atrio A, Perez A, Cuende E, Albarran F, Turrion A, et al. Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis. Arthritis Res Ther. 2012;14(4):R175. doi: 10.1186/ar3928. PubMed DOI PMC

Chen Z, Andreev D, Oeser K, Krljanac B, Hueber A, Kleyer A, et al. Th2 and eosinophil responses suppress inflammatory arthritis. Nat Commun. 2016;7:11596. doi: 10.1038/ncomms11596. PubMed DOI PMC

Choy EH, Bernasconi C, Aassi M, Molina JF, Epis OM. Treatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic agent in a global comparative observational study. Arthritis Care Res. 2017;69:1484–1494. doi: 10.1002/acr.23303. PubMed DOI PMC

Conte Fde P, Barja-Fidalgo C, Verri WA, Jr, Cunha FQ, Rae GA, Penido C, et al. Endothelins modulate inflammatory reaction in zymosan-induced arthritis: participation of LTB4, TNF-alpha, and CXCL-1. J Leukoc Biol. 2008;84:652–660. doi: 10.1189/jlb.1207827. PubMed DOI

Dahlqvist SR, Nilsson TK, Norberg B. Thrombocytosis in active rheumatoid arthritis. Relation to other parameters of inflammatory activity and confounding effect of automated cell counting. Clin Rheumatol. 1988;7:335–341. PubMed

Espinoza F, Le Blay P, Combe B. Biologic disease-modifying antirheumatic drug (bDMARD)-induced neutropenia: a registry from a retrospective cohort of patients with rheumatic diseases treated with 3 classes of intravenous bDMARD. J Rheumatol. 2017;44:844–849. doi: 10.3899/jrheum.150457. PubMed DOI

Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Meth. 2007;39:175–191. doi: 10.3758/bf03193146. PubMed DOI

Fu H, Qin B, Hu Z, Ma N, Yang M, Wei T, et al. Neutrophil- and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis. Clin Lab. 2015;61:269–273. PubMed

Gaber T, Hahne M, Strehl C, Hoff P, Dorffel Y, Feist E, et al. Disentangling the effects of tocilizumab on neutrophil survival and function. Immunol Res. 2016;64:665–676. doi: 10.1007/s12026-015-8770-x. PubMed DOI

Hashimoto M, Fujii T, Hamaguchi M, Furu M, Ito H, Terao C, et al. Increase of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis. PloS One. 2014;9(5):e98202. doi: 10.1371/journal.pone.0098202. PubMed DOI PMC

Hensel M, Gradel L, Kutz A, Haubitz S, Huber A, Mueller B, et al. Peripheral monocytosis as a predictive factor for adverse outcome in the emergency department: Survey based on a register study. Medicine. 2017;96(28):e7404. doi: 10.1097/MD.0000000000007404. PubMed DOI PMC

Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13:357–368. PubMed

Kihara M, Davies R, Kearsley-Fleet L, Watson KD, Lunt M, Symmons DP, et al. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Clin Rheumatol. 2017;36:241–250. doi: 10.1007/s10067-016-3485-5. PubMed DOI PMC

Maeda K, Baba Y, Nagai Y, Miyazaki K, Malykhin A, Nakamura K, et al. IL-6 blocks a discrete early step in lymphopoiesis. Blood. 2005;106:879–885. doi: 10.1182/blood-2005-02-0456. PubMed DOI PMC

Michaud TL, Rho YH, Shamliyan T, Kuntz KM, Choi HK. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med. 2014;127:1208–1232. doi: 10.1016/j.amjmed.2014.06.012. PubMed DOI

Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford) 2012;51:2252–2261. doi: 10.1093/rheumatology/kes217. PubMed DOI

Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1113–1136. doi: 10.1136/annrheumdis-2016-210713. PubMed DOI

Negrei C, Bojinca V, Balanescu A, Bojinca M, Baconi D, Spandidos DA, et al. Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches. Exp Ther Med. 2016;11:1177–1183. doi: 10.3892/etm.2016.3045. PubMed DOI PMC

Orlewska E, Ancuta I, Anic B, Codrenau C, Damjanov N, Djukic P, et al. Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit. 2011;17(4):SR1–S13. PubMed PMC

Paul SK, Montvida O, Best JH, Gale S, Pethoe-Schramm A, Sarsour K. Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data. Semin Arthritis Rheum. 2018;47:478–484. doi: 10.1016/j.semarthrit.2017.08.001. PubMed DOI

Picchianti Diamanti A, Lagana B, Cox MC, Pilozzi E, Amodeo R, Bove M, et al. TCD4(pos) lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFalpha blocking agents. J Transl Med. 2017;15(1):38. doi: 10.1186/s12967-017-1135-6. PubMed DOI PMC

Rigby WFC, Lampl K, Low JM, Furst DE. Review of routine laboratory monitoring for patients with rheumatoid arthritis receiving biologic or nonbiologic DMARDs. Int J Rheumatol. 2017;2017:9614241. doi: 10.1155/2017/9614241. PubMed DOI PMC

Rudan I, Sidhu S, Papana A, Meng SJ, Xin-Wei Y, Wang W, et al. Prevalence of rheumatoid arthritis in low- and middle-income countries: A systematic review and analysis. J Global Health. 2015;5(1):010409. doi: 10.7189/jogh.05.010409. PubMed DOI PMC

Sag S, Sag MS, Tekeoglu I, Kamanli A, Nas K, Acar BA. Relationship of hematologic markers with IL-17 and IL-1 beta in patients with rheumatoid arthritis. J Back Musculoskelet Rehabil. 2018;31:703–707. doi: 10.3233/BMR-170903. PubMed DOI

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009;(4):CD007848. doi: 10.1002/14651858.CD007848.pub2. PubMed DOI PMC

Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794. doi: 10.1002/14651858.CD008794.pub2. PubMed DOI PMC

Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–977. doi: 10.1136/annrheumdis-2016-210715. PubMed DOI

Suzuki S, Nakano S, Ando S, Matsudaira R, Kanai Y, Yamanaka K, et al. Hepcidin-25 gives an indication of the therapeutic effectiveness of tocilizumab in rheumatoid arthritis - Relationship between disease activity of rheumatoid arthritis and anemia. Rev Bras Reumatol Engl Ed. 2017;57:637–640. doi: 10.1016/j.rbre.2016.09.004. PubMed DOI

Syed KM, Pinals RS. Leukocytosis in rheumatoid arthritis. J Clin Rheumatol. 1996;2:197–202. PubMed

Tanaka T, Ogata A, Narazaki M. Tocilizumab for the treatment of rheumatoid arthritis. Exp Rev Clin Immunol. 2010;6:843–854. doi: 10.1586/eci.10.70. PubMed DOI

Tanaka Y. Current concepts in the management of rheumatoid arthritis. Korean J Intern Med. 2016;31:210–218. doi: 10.3904/kjim.2015.137. PubMed DOI PMC

Tekeoglu I, Gurol G, Harman H, Karakece E, Ciftci IH. Overlooked hematological markers of disease activity in rheumatoid arthritis. Int J Rheum Dis. 2016;19:1078–1082. doi: 10.1111/1756-185X.12805. PubMed DOI

Tian T, Wang M, Ma D. TNF-alpha, a good or bad factor in hematological diseases? Stem Cell Investig. 2014;1:12. doi: 10.3978/j.issn.2306-9759.2014.04.02. PubMed DOI PMC

Ulich TR, del Castillo J, Guo K, Souza L. The hematologic effects of chronic administration of the monokines tumor necrosis factor, interleukin-1, and granulocyte-colony stimulating factor on bone marrow and circulation. Am J Pathol. 1989;134:149–159. PubMed PMC

Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–1023. doi: 10.1056/NEJMra041809. PubMed DOI

Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology (Oxford) 2014;53:1321–1331. doi: 10.1093/rheumatology/keu035. PubMed DOI

Yazici S, Yazici M, Erer B, Calik Y, Ozhan H, Ataoglu S. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets. 2010;21:122–125. doi: 10.3109/09537100903474373. PubMed DOI